Scott + Scott, LLP, a global investor rights law firm, reminds investors that Monday, February 1, 2016 is the deadline for investors to file lead plaintiff papers in the securities lawsuit against Vital Therapies, Inc. (VTL). To get information on filing lead plaintiff papers, or to join the lawsuit, go to: http://www.scott-scott.com/pop.php?page=join&case_id=2715.

There is no cost or obligation to you.

You can also call Joseph Halloran, Esq. at (646) 582-0121 or email jhalloran@scott-scott.com for information about the lawsuit.

About the Lawsuit

The complaint alleges that throughout the class period, defendants issued materially false and misleading statements and/or failed to disclose material information regarding the Company’s ELAD System studies, VTI-208, VTI-210, and VTI-212, including (a) the studies’ independent significance; (b) the degree to which the studies were interrelated; and (c) that in the case of the failure of the VTI-208 trial, the Company would not continue the VTI-210 trial. On August 21, 2015, after the market closed, Vital Therapies announced that the VTI-208 trial had “failed to meet the primary endpoint of overall survival through at least 91 days…” and that the Company would stop the VTI-210 and VTI-212 clinical trials. Upon this news, Vital Therapies shares plunged 73.4% to close at just $3.65 per share the next trading day.

To join the suit, go to: http://www.scott-scott.com/pop.php?page=join&case_id=2715. Scott + Scott, LLP has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.